YayaNews LogoYaya Financial News
SECTION

#Immunotherapy

Total 2 related articles

Live wire →

NewsTag

Featured

Sanofi's Tzield Receives FDA Approval for Stage 3 Type 1 Diabetes Treatment, Boosting US Stock
Lead report
美股

Lead report

Sanofi's Tzield Receives FDA Approval for Stage 3 Type 1 Diabetes Treatment, Boosting US Stock

Sanofi announced FDA approval of Tzield for stage 3 type 1 diabetes, filling an immunomodulatory therapy gap. Market response is positive, with analysts projecting peak sales of $2-3 billion, strengthening the company's metabolic disease pipeline.

YayaNews2026-06-13 22:423 min
来源: Seeking Alpha
美股

Aethlon Tumor Trial Expands to 3-6 Patients: Hemopurifier Clinical Progress Analysis

Aethlon Medical announces expansion of Hemopurifier tumor trial Cohort 3 to 3-6 patients, focusing on exosome clearance combined with immunotherapy. This article analyzes the technology, financial background, competitive landscape, and key investor considerations.

YayaNews2026-06-11 08:323 min来源: Seeking Alpha
Aethlon Tumor Trial Expands to 3-6 Patients: Hemopurifier Clinical Progress Analysis

More Related Articles